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T-Cell Manufacture for Treatment of Acute Lymphoblastic Leukemia
Abstract
Adoptive T-cell therapy is a recent medical development that has shown clinical success in treating relapsed
acute lymphoblastic leukemia (ALL), a common form of cancer with a poor prognosis. Ironically, the
treatment’s greatest advantage is at the same time deterring large pharmaceutical companies from
commercializing it. Adoptive T-cell therapy is successful in treating ALL largely because it takes a patient’s
own cells and engineers them to fight the cancer. While the autologous nature of the treatment helps to
incorporate the engineered T-cells into the patient’s body, it also makes each treatment patient-specific. This
does not fit into the paradigm of large pharmaceutical companies, who want “off the shelf ” drugs. Critics claim
that adoptive T-cell therapy is a “boutique” treatment that is too costly and too impractical to commercialize.
Our group performed a profitability analysis on a commercial-scale T-cell manufacturing facility based in
Philadelphia and found that it could in fact be profitable. Furthermore, we pinpointed a cell separation step in
the current procedure that was not optimal. We modeled the separation and determined an optimal operating
protocol that would decrease the failure rate from 10% to 1%, increasing profitability in our facility by 25
million dollars.
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PROFESSOR LEONARD A. FABIANO                                                                                                                                       APRIL 14, 2015 
DR. MIRIAM WATTENBARGER 
DEPARTMENT OF CHEMICAL AND BIOMOLECULAR ENGINEERING 
UNIVERSITY OF PENNSYLVANIA 
PHILADELPHIA, PA 19104 
 
Professor Fabiano and Dr. Wattenbarger, 
 
In the fall semester of 2014, you asked us to improve and scale up the T-cell manufacturing 
process being used at the Hospital of the University of Pennsylvania. Although still early in its 
development, adoptive T-cell therapy has shown clinical success in the treatment of acute 
lymphoblastic leukemia (ALL) to such great effect that it has contributed to Science magazine 
naming cancer immunotherapy the breakthrough of 2014. Despite the initial success of T-cell 
therapeutics for the treatment of ALL, commercialization of the treatment has not yet occurred. 
Due to the lack of precedent for T-cell therapeutics, two challenges arise. The first is that there is 
no basis for assessing the profitability of the scaled up process. The second is that tailored 
equipment has not yet been designed for T-cell manufacture, leaving manufacturers using 
suboptimal equipment and protocols. This past semester, our group attempted to tackle both 
problems. 
 
First, we performed a market and competitive analysis to determine whether building a 
commercial T-cell manufacturing plant for the production of ALL therapeutics would be 
profitable. Our calculations indicated that a commercial T-cell process was indeed profitable. As 
a second component of our project, we modeled a cell separator and developed a protocol for 
optimal separation of red blood cells from white blood cells. We predict that our proposed 
modification will improve the overall success rate of the procedure and accordingly, the 
profitability as well. 
 
Sincerely 
 
Amit Pujari                                                 Chi-Wei Man                                             Jinsang Park 
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Chapter 1: Abstract 
1.0: Abstract 
 Adoptive T-cell therapy is a recent medical development that has shown clinical success 
in treating relapsed acute lymphoblastic leukemia (ALL), a common form of cancer with a poor 
prognosis. Ironically, the treatment’s greatest advantage is at the same time deterring large 
pharmaceutical companies from commercializing it. Adoptive T-cell therapy is successful in 
treating ALL largely because it takes a patient’s own cells and engineers them to fight the 
cancer. While the autologous nature of the treatment helps to incorporate the engineered T-cells 
into the patient’s body, it also makes each treatment patient-specific. This does not fit into the 
paradigm of large pharmaceutical companies, who want “off the shelf” drugs. Critics claim that 
adoptive T-cell therapy is a “boutique” treatment that is too costly and too impractical to 
commercialize. Our group performed a profitability analysis on a commercial-scale T-cell 
manufacturing facility based in Philadelphia and found that it could in fact be profitable. 
Furthermore, we pinpointed a cell separation step in the current procedure that was not optimal. 
We modeled the separation and determined an optimal operating protocol that would decrease 
the failure rate from 10% to 1%, increasing profitability in our facility by 25 million dollars. 
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Chapter 2: Introduction 
2.0: Background 
 T-cells are a type of white blood cell (leukocyte) that serve as the initiators of the 
adaptive immune response. They possess a crucial T-cell receptor that recognizes exogenous 
cells. Note that exogenous can refer to either an invading pathogen or a tumor cell, which is a 
mutated version of an endogenous cell. To become activated and initiate the immune response, 
the T-cell must recognize an antigen, which is a small identifying protein, bound to major 
histocompatibility complex (MHC). MHC “processes” the antigen such that it can be recognized 
by the T-cell. See figure 2.1 for a schematic of T-cell activation. Once activated, T-cells trigger a 
cascade of events. Most notably, they expand and release cytokines, which are small signaling 
proteins that stimulate other immune cells. This causes immune cells to target and destroy cells 
presenting the antigen of interest. A disease such as acute lymphoblastic leukemia (ALL) is 
lethal because tumor cells down-regulate MHC. Without MHC, T-cells cannot recognize 
antigens and become activated. Thus, the adaptive immune response is effectively shut down. 
   
 
 
 
 
 
 
 
 
 
 
Figure 2.1: T-cell activation.1 The 
T-cell receptor on the cytotoxic T-
cell recognizes the antigen/MHC 
complex represented by the blue 
triangles and green rectangles. This 
initiates the adaptive immune 
response. 
Tumor cell 
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 A research team at the University of Pennsylvania has found a way to engineer T-cells to 
bypass the tumor escape mechanism of leukemic tumor cells. This method, dubbed chimeric 
antigen receptor therapy involves genetically engineering T-cells to replace their natural receptor 
binding domain with an antibody binding domain, which allows the T-cell to recognize antigens 
without MHC. A natural T-cell receptor comprises three domains: a receptor domain which 
recognizes antigen and MHC complexes, an intermembrane domain that anchors the receptor to 
the T-cell, and a signaling domain which releases molecules that signal for the destruction of 
pathogenic cells. Figure 2.2A shows this modified chimeric antigen receptor (CAR). As the 
figure shows, only the binding domain of the receptor is replaced. The T-cell signaling domain is 
left intact, allowing for the regular immune response signaling cascade to occur once the CAR 
cell has been activated. CAR T-cells are able to recognize antigens bound to the surface of tumor 
cells without the need for MHC, as figure 2.2B and figure 2.2C show.  
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.2: A) Diagram of chimeric antigen receptor (CAR). 2 The signaling domain, labeled as “ligand 
binding domain” is now an antibody binding domain, which allows it to recognize antigens without requiring 
the presence of MHC. The transmembrane and signaling domains remain intact. B) Activation of an 
unmodified T-cell. This requires recognition of an antigen bound to MHC. C) Activation of a chimeric antigen 
receptor T-cell.3 This type of cell can recognize antigens on tumor cells without requiring the antigen to be 
bound to MHC. 
B A 
C 
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Initial results of CAR therapy have been successful. In a clinical trial published October 
of 2014 in the New England Journal of Medicine, Dr. Carl June and his research team showed 
that their CAR therapy was extremely effective in treating patients with ALL. Out of the 30 
patients enrolled in the study, 27 of them experienced complete remission, a 90% success rate.4 
This result is made even more impressive because most of the patients had already undergone 
chemotherapy and stem cell infusions, both of which had failed. Thus, adoptive T-cell therapy is 
a new form of medicine that is likely to entirely disrupt the cancer therapy market. 
 T-cell manufacturing is the process by which a patient’s endogenous T-cells are 
converted into therapeutics. As the name suggests, adoptive T-cell therapy involves removing a 
patient’s T-cells, culturing and genetically modifying them ex vivo, then infusing them back into 
the patient. Figure 2.3 illustrates the general process in more detail. In the first step of apheresis, 
the blood is removed from the patient, and the white blood cells, containing the T-cells, are 
separated from the rest of the blood. Next, the cells are cultured ex vivo and expanded. This step 
involves using antigen presenting beads to stimulate growth and division of T-cells. They are 
then genetically modified using synthetic biology to convert T-cells into CAR T-cells. In the 
final treatment step of reinfusion, cells are washed and then infused back into the patient. 
Following treatment, the patient is monitored in a medical facility for signs of improvement or 
decline. The major advantage of the process is that it is autologous, meaning that the adopted T-
cells are derived from the patient’s own cells, which reduces chances of immunogenicity 
(patient’s immune cells rejecting the introduced therapeutic). Currently, the Clinical Cell and 
Vaccine Production Facility (CCVPF) at the Hospital of the University of Pennsylvania is one of 
only several facilities engaged in the manufacture of T-cell therapeutics. Their therapeutic is 
called CTL019. 
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Figure 2.3: Schematic of T-cell manufacture.5 Step 1: whole blood, containing T-cells is removed from the body, and the T-cells 
are purified. Step 2: T-cells are grown and expanded ex vivo, Step 3: T-cells are genetically modified to better fight a targeted 
disease. Step 4: Modified T-cells are reinfused back into the patient’s body. 
  
1 
2 
3 
4 
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 The goal of our project was to design a scaled up commercial facility for the manufacture 
of T-cell therapeutics to treat ALL. As part of the design, we assessed whether or not the 
commercial facility was profitable and worth pursuing given the available market. In addition, 
we also modeled a cell separation step to increase the purity of target T-cells in the product 
stream. Our method of showing increased purity was calculating the difference between average 
residence times of target and waste cells. We propose that our purer T-cell products will increase 
the profitability of our plant. 
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2.1: Project charter and scope 
Project Name Adoptive T-cell manufacture for treatment of acute lymphoblastic 
leukemia 
Project 
Champions 
Dr. Miriam Wattenbarger, UPenn; Dr. Bruce Levine, Hospital of the 
University of Pennsylvania 
Project Leaders Amit Pujari, Chi-Wei Man, Jinsang Park 
Specific Goals Design a commercial-scale T-cell manufacturing facility for the 
production of CTL019 to treat acute lymphoblastic leukemia 
Project Scope In-Scope 
 Market and competitive analysis 
 Demographic analysis of facility location 
 cGMP compliance 
 Commercial facility equipment specifications 
 Cell separator operating procedure 
 Profitability analysis 
Out-of-Scope 
 Packaging and distribution of T-cell therapeutics 
 Clinical trials for FDA approval of therapy 
 Molecular biology of T-cell manufacturing process 
Deliverables  Cell separation device design 
 Modeling of cell release profiles for various operating conditions 
 Profitability analysis of commercial manufacturing facility 
Timeline Complete report of plant specifications and profitability before April 14, 
2015 
  
14 
 
2.2: Innovation map  
15 
 
2.3: Chapter 2 References 
1. Colgate Immunology (and Virology) Blog. (n.d.). Retrieved April 6, 2015, from 
http://colgateimmunology.blogspot.com/2013_09_01_archive.html 
2. Kalos, M., & June, C. (n.d.). Adoptive T Cell Transfer for Cancer Immunotherapy in the 
Era of Synthetic Biology. Immunity, 49-60. 
3. Restifo, N., & Rosenberg, S. (n.d.). Adoptive cell transfer as personalized 
immunotherapy for human cancer. Science, 348(6230), 62-68. 
4. June, C. (n.d.). Chimeric Antigen Receptor T Cells for Sustained Remissions in 
Leukemia. New England Journal of Medicine, 371(16), 1507-1517. 
5. Maus, M., Fraietta, J., Levine, B., Kalos, M., Zhao, Y., & June, C. (2014). Adoptive 
Immunotherapy for Cancer or Viruses. Annual Review of Immunology, 189-225. 
  
16 
 
Chapter 3: Concept stage 
3.0: Market and competitive analysis 
The goal of this therapy is to produce a T-cell modification in patients with severe acute 
lymphoblastic leukemia (ALL). While the therapy has the potential to treat other conditions 
including HIV/AIDS, the scope of this project will only include the ALL process. While the total 
number of patients with ALL in the US is approximately 66,000, there are an estimated 6250 
new ALL patients and 1450 deaths from ALL each year. ALL disproportionately affects younger 
populations; it is the most common form of cancer found in patients aged 0 to 14 (American 
Cancer Society, 2014). This form of leukemia is characterized by the presence of too many 
lymphoblasts in the bone marrow and can quickly spread to other parts of the body due to the 
distribution channels within the immune system. While life expectancy has been slightly 
increasing, few of the currently used treatments have consistently shown complete remission of 
the disease.  
 According to the Cancer Treatment Centers of America, the current treatment options 
available to ALL patients include chemotherapy, stem cell transplant, radiation therapy, and 
immunotherapy. Many of these treatments are commonly used options for other forms of cancer 
as well. Approximately 80% of ALL patients who undergo chemotherapy will go into remission, 
although the cancer eventually returns in some cases. While many of the treatments available are 
effective, even if temporarily, they often come with lasting side effects. Most recognizable of 
these would be the associated hair loss due to radiation and chemotherapies, drop in blood cell 
counts, mouth sores and ulcers, and general tiredness. Of the available treatments, our Adoptive 
T-cell therapy (immunotherapy) is the first to show results of complete remission in almost all 
patients, and without any severe, lasting side effects. Currently in Phase I and II clinical trials, 
the adoptive T-cell therapy is being considered for use in patients who have exhausted the other 
potential treatments. If approved, the adoptive T-cell therapy could be considered for treatment 
of all ALL patients to significantly increase the likelihood of complete remission.  
 Creating a facility like the cGMP site where the clinical trials are currently being 
conducted is a significant barrier to entry. Due to the strict guidelines required for an approved 
Good Manufacturing Practice (GMP), building such a facility can be extremely expensive and 
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laborious. In addition to the high construction costs, the facility also requires additional costs and 
labor to continue operating. There are however several such facilities in existence including ones 
in Boston, Seattle, Ireland, New York, Cincinnati, Utah, California and Miami. While these 
facilities have the potential capability to produce a similar therapy, most are not currently 
producing similar therapies. Table 3.1 shows many of the currently operating cGMP facilities as 
well as some available information regarding size and history about each of them.  
Table 3.1: Potential competing cGMP facilities in existence.6,7,8,9,10,11,12,13,14,15,16,17 
Name Location Size Founded 
Harvard Cancer 
Center 
Cambridge, MA - 1996 
Fred Hutchinson 
Cancer Research 
Center 
Seattle, WA - 1975 
REMEDI Ireland 250 m2 - 
Waisman 
Biomanufacturing 
Madison, WI 7 rooms 2001 
Roswell Park 
Cancer Institute 
Buffalo, NY 2574 ft2, 7 rooms 2008 
Baylor University Waco, TX 12,000 ft2 1998 
Hoxworth Blood 
Center 
Cincinnati, OH - - 
University of Utah Salt Lake City, UT 9,222 ft2, 7 rooms 1996 
CESCA 
Laboratories 
New York City, NY - - 
City of Hope Philadelphia, PA 10,000 ft2 - 
Case Western 
University 
Cleveland, OH 10,000 ft2 - 
Batavia Bioservices Netherlands - - 
University of Miami Miami, FL - 2008 
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Seattle Children’s, a hospital system located in Seattle, Washington is one of the few 
direct competitors to the process. The center opened its Program for Cell and Gene Therapy in 
2014 and is already conducting Phase I and II clinical trials for their own adoptive t-cell therapy 
for leukemia, and specifically ALL, as it is the most common form of cancer diagnosed in 
children. The Memorial Sloan Kettering Cancer Center, initially founded in 2003 in New York 
City, NY, has also begun clinical trials on an adoptive t-cell therapy for ALL that functions 
similarly to the University of Pennsylvania process. As the only potential competitor located 
within the region surrounding Philadelphia, Sloan Kettering would pose the only challenge to 
control of the market share. The capacity and sales projections will be further discussed in the 
economic analysis.  
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3.1: Market share analysis 
When determining the share of the market that can be obtained, the target customer base 
was limited to the areas surrounding the intended facility location. While blood samples taken 
from the patient are typically cryo-preserved and shipped via an airplane, transportation costs can 
be severely reduced if the clinic where apheresis occurs is located within four hours driving 
distance of the processing facility. In these situations, the samples can be immediately 
transported as fresh samples, saving both time and money. Using Philadelphia, PA as the facility 
location, figure 3.1 shows a graphical representation of expected market region: 
 
Figure 3.1: Area reachable by car within four hours from Philadelphia, assuming an average 60 mph speed. 
 
Of the 66,000 patients with ALL in the country, accounting for the relative size and 
population density of the intended region puts approximately 9479 ALL patients currently living 
within the area4. 898 new ALL patients are discovered within this region every year, increasing 
the potential market size. The Memorial Sloan Kettering Cancer Center is located within the 
desired region and would thus serve as the main potential competitor for the product.  
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According to a study by H. G. Grabowski and J.M. Vernon5, the effective patent life of 
new pharmaceutical drugs and therapies is close to twelve years (2000). With this patent life, an 
operating company could expect to maintain high profits for these twelve years before the 
introduction of generics to the market would drastically reduce the achievable revenue due to 
competition. Over the course of twelve years, approximately 20,255 ALL patients will be 
available for treatment. Due to the high expected price of the treatment, it is likely that many 
individuals with weak or no health insurance coverage will not be able to opt for the treatment. 
According to a Kaiser Family Foundation report, the number of Americans without health 
insurance was as high as 50 million in 2010. While that number may have decreased by 2015, 
this statistic still significantly affects the potential market size as the poor are disproportionately 
likely to miss diagnosing ALL in its early stages when less drastic treatments would be effective.  
 
3.2: Customer requirements 
Acute lymphoblastic leukemia affects 66,000 individuals in the US and that number 
grows by 6250 each year. Scaling these statistics down to account only for the region located 
within a reasonable driving distance of the facility, the region would contain 9479 patients with 
898 new patients each year. The product must match fitness-to-standard because the quality of 
the therapy cannot be compromised as the product is directly injected into the patients. The 
cGMP facility requirements are in place to ensure that all products are safe for biological 
exposure. 
 
3.3: cGMP facilities and manufacturing 
The US is generally stricter than most other countries when it comes to industrial 
regulations. With the increasing frequency of drugs and other biological supplements being 
brought to the market, it was necessary to establish a standard by which to ensure that all 
substances purposely administered to patients are safe. Good manufacturing practice (GMP) was 
first proposed during the 1963 GMP Regulations and Amendments to promote its effectiveness 
and increased safety (Gee). With the increasing popularity and effectiveness of cell treatments 
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like the adoptive T-cell therapy and stem cell therapy, the medical community recognized the 
need for a standard policy regarding the handling of the manufacturing process for these 
treatments. 
These GMP facilities were carefully planned to provide an efficient process flow. It is 
generally accepted that stand-alone facilities are advantageous to GMP sections of existing 
facilities, because the GMP practices can be set in effect for the entire building, with no 
confusion as to its implementation. Facilities usually function best with a unidirectional travel 
pattern along a central passage. As seen in figure 3.2, the doors on the left are likely the 
individual cell processing rooms, which only handle one patient at a time. The door on the right 
is likely a central equipment storage room for common use by workers from all of the cell 
processing rooms.  
 
Figure 3.2: A typical cGMP main corridor layout.18 
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 HEPA air filtration is required in all cGMP facilities, as seen in subpart C of table 3.2. 
HEPA filtration creates a higher pressure within the facility to prevent any contaminants in the 
air from incidentally entering the rooms. In addition to this system, there are a number of 
precautions in place to ensure sanitary conditions. Personal protective equipment (PPE), 
specialized windows for quick transfer of any materials or waste, as well as frequent cleaning are 
just a few of these. When designing the layout of a cGMP facility, architects seek to create two 
distinct circulations, one for materials/services and one for workers. The materials circulation is 
separated into clean and dirty paths to distinguish between the product and the waste, 
respectively. Smaller cell processing rooms are used to isolate the process pathway for each 
individual patient. The cells from any given patient remain in the same room throughout the 
entire process and equipment are wheeled into the room from the central storage room.  
 The specific policies for cGMP facilities are outline into various subparts, as seen in table 
3.2. Each subpart covers a specific aspect of regulation required to pass cGMP guidelines. The 
AABB Committee on Inspection and Accreditation was established in 1960 to help certain 
regulated facilities meet local, state and federal requirements. It later expanded to also govern the 
control of cellular therapy product services in the 1990’s. Almost all blood banks and transfusion 
centers are now members of AABB and thus comply with the requirements of the Clinical 
Laboratory Improvement Amendments.  
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Table 3.2: Expected components of a GMP facility include the following subparts 
Subpart Explanation 
A Must continuously update standards to match the current practices 
B Must contain a quality control (QC) unit with the authority to approve/reject 
components, review production records, and approve/reject all procedures or 
specifications 
Personnel must be trained, educated and provided the proper personal hygiene and 
health habits 
C Building and facilities must contain proper size and layouts, a ventilation (HVAC) 
and air filtration system, plumbing, washing and toilet facilities, and maintenance 
and cleaning designed to prevent contamination 
D All equipment must be designed with the proper construction, cleaning and 
maintenance standards to prevent contamination, mix-ups and errors 
E All components, containers and closures must contain written procedures describing 
proper handling, receipt and storage, testing and approval 
F Production controls must contain written procedures for the charging of 
components, identifying equipment, sampling, and contamination control 
Any deviations from these should incur investigation with a good root cause 
analysis and actions to correct the situation 
G All packaging and labeling must contain written details for examination, operation, 
inspection confirmation and expiration dates 
H All warehouse storage must be quarantined and appropriately stored for conditions 
appropriate to the product 
The distribution should have proper inventory documentation and tracking 
I All laboratories should confirm to appropriate specifications and assure the strength, 
purity and stability of all samples are ideal 
J Records and reports should be stored and available for inspection on request 
including any logs, files or records 
K Drug products should be quality confirmed based on controls and requirements 
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3.4: Product concepts 
The options available to current ALL patients include a combination of different 
techniques depending on the severity and responsiveness of the particular patient. Before the 
development of immunotherapy, the typical options consisted of chemotherapy, interferon 
therapy, radiation therapy, stem cell transplantation and surgery. Stem cell treatment is usually 
considered last and in combination with the other forms of therapy. Immunotherapy, such as the 
adoptive T-cell treatment is unique, because it utilizes the immune system of the patient to 
combat the disease. The first immunotherapy for ALL to receive FDA approval is Amgen’s 
Blincyto (Bloomberg Business, 2014). This drug facilitates interaction between CD3 proteins on 
t-cells and the CD19 proteins characteristic of this cancer. Unlike the adoptive T-cell therapy, 
this process does not require modification of the T-cells, but is resultantly less effective. A 
standard course of treatment for Blincyto costs $178,000 for two four-week treatments. While 
Blincyto is less invasive and can be administered without a turnaround time, clinical trials 
showed complete remission in only 32 percent of patients.  
A common chemotherapeutic drug for ALL is asparaginase. Costs of a full course of 
treatment can soar upwards of $57,893 for a 30 week treatment and up to around $113,558 under 
certain circumstances (Tong, et al.)19. While this treatment course, when administered with an 
early diagnosis can be effective in some cases, the process takes many months to complete and 
results in side effects commonly associated with chemotherapy including hair loss and 
compromised immune systems. The outlook for patients with ALL varies based on a number of 
factors, but younger patients do tend to have a significantly longer life expectancy and chance of 
remission. With early diagnosis, children with ALL have a roughly 80% chance of living longer 
than five years. Approximately 40% of adults diagnosed with ALL will live longer than five 
years.  
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3.5: Superior product concept 
The adoptive T-cell therapy surpasses the alternative treatments in multiple aspects. Early 
clinical trials in ALL patients who had exhausted all other options showed a greater than 57 
percent rate of complete remission (NY Times, 2014). Tumors and other significant signs of the 
cancer typically disappear within two weeks of the treatment. While the T-cells are attacking the 
tumor, the body usually exhibits cytokine release syndrome that manifests itself in fever, aches, 
drops in blood pressure and trouble breathing. The survival rate for this study was even greater. 
The adoptive T-cell therapy is also potentially much cheaper than alternative options. Without 
the need for large reactors or equipment to produce a drug on an industrial scale, the cost of 
production for the therapy drops well below the price of the main competitors. Administration of 
the therapy is also easily facilitated; adoptive T-cell therapy requires a single injection, close to 
two weeks after the initial blood collection. Patients with severe ALL often do not have long life 
expectancies and the adoptive T-cell therapy would ensure that more patients survive long 
enough to receive proper treatment.  
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Chapter 4: Process flow and material balance 
4.0 Process flow diagram 
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4.1: Overall material balance for a treatment 
PFD-01 
Component Unit Initial 
Product 
Additional 
Input 
Waste 
Output 
Final 
Product 
Volume mL 450 11040.02 11390.02 100 
Red Blood Cell cells/mL 4.44×108 0 1.76×107 1.90×105 
White Blood Cell cells/mL 3.33×107 0 1.70×106 5.90×108 
Granulocytes cells/mL 4.02×106 0 1.56×105 4.10×105 
Monocytes cells/mL 6.98×106 0 2.70×105 7.39×105 
T-cell cells/mL 2.22×107 0 1.26×106 5.89×108 
Suppressor T-cell cells/mL 1.11×105 0 4.41×103 1.69 
Platelets cells/mL 1.04×109 0 3.98×107 1.84×108 
Plasma mL 244.35 0 244.29 0.06 
CD4 Microbeads mL 0 0.02 0.02 0 
CD3/28 Dynabeads mL 0 0.84 0.84 0 
Buffer mL 0 1100 1085 15 
Cell Culture Media mL 0 9940 9805 135 
Glucose g/mL 0 1.00×10-3 1.24×10-4 1.12×10-4 
Glutamine g/mL 0 2.92×10-4 0 0 
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4.2: Stream summary for PFD 01  
Stream Name S-C1 S-C2 S-C3 S-01 S-02 
Source P-C1 P-C2 P-C2 P-C3  
Destination P-C2 P-C3 P-C1 P-01 P-01 
Stream Properties Unit      
Temperature °C 23 23 23 23 23 
Pressure  Atm 1 1 1 1 1 
Component 
Volume mL 10000 450 9550 450 150 
Red Blood Cell cells/mL 5.20×109 4.44×108 5.42×109 4.44×108 0 
White Blood Cell cells/mL 7.50×106 3.33×107 6.29×106 3.33×107 0 
Granulocytes cells/mL 9.07×105 4.02×106 7.60×105 4.02×106 0 
Monocytes cells/mL 1.57×106 6.98×106 1.32×106 6.98×106 0 
T-cell cells/mL 4.99×106 2.22×107 4.19×106 2.22×107 0 
Suppressor T-cell cells/mL 2.51×104 1.11×105 2.10×104 1.11×105 0 
Platelets cells/mL 3.50×108 1.04×109 3.17×108 1.04×109 0 
Plasma mL 5430 244.35 5185.65 244.35 0 
CD4 Microbeads mL 0 0 0 0 0 
CD3/28 Dynabeads Beads/mL 0 0 0 0 0 
Buffer mL 0 0 0 0 150 
Cell Culture Media mL 0 0 0 0 0 
Glucose g/mL 0 0 0 0 0 
Glutamine g/mL 0 0 0 0 0 
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Stream Name S-03 S-04 S-05 S-06 S-07 
Source  P-03 P-03  P-03 
Destination P-03  P-04 P-03  
Stream Properties Unit      
Temperature °C 23 23 23 23 23 
Pressure  Atm 1 1 1 1 1 
Component 
Volume mL 600 540 60 750 750 
Red Blood Cell cells/mL 3.33×108 3.67×108 3.33×107 0 2.40×106 
White Blood Cell cells/mL 2.50×107 1.85×107 8.27×107 0 3.44×106 
Granulocytes cells/mL 3.02×106 3.17×106 1.67×106 0 6.93×104 
Monocytes cells/mL 5.23×106 5.48×106 3.00×106 0 1.25×105 
T-cell cells/mL 1.66×107 9.80×106 7.80×107 0 3.24×106 
Suppressor T-cell cells/mL 8.33×104 9.25×104 1.30×103 0 2.71×101 
Platelets cells/mL 7.83×108 6.48×108 2.00×109 0 1.31×108 
Plasma mL 244.35 219.92 24.44 0 18.31 
CD4 Microbeads mL 0 0 0 0 0 
CD3/28 Dynabeads beads/mL 0 0 0 0 0 
Buffer mL 150 135 15 750 693 
Cell Culture Media mL 0 0 0 0 0 
Glucose g/mL 0 0 0 0 0 
Glutamine g/mL 0 0 0 0 0 
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Stream Name S-08 S-09 S-10 S-11 S-12 
Source P-03  P-04 P-04  
Destination P-04 P-04  P-05 P-05 
Stream Properties Unit      
Temperature °C 23 23 23 23 23 
Pressure  Atm 1 1 1 1 1 
Component 
Volume mL 60 200 200 60 0.89 
Red Blood Cell cells/mL 3.33×106 0 5.00×104 3.17×106 0 
White Blood Cell cells/mL 3.97×107 0 5.95×105 3.77×107 0 
Granulocytes cells/mL 8.00×105 0 1.20×104 7.60×105 0 
Monocytes cells/mL 1.44×106 0 2.16×104 1.37×106 0 
T-cell cells/mL 3.74×107 0 5.62×106 3.56×107 0 
Suppressor T-cell cells/mL 3.13×102 0 9.29×101 3.13 0 
Platelets cells/mL 3.59×108 0 5.39×106 3.23×108 0 
Plasma mL 6.12 0 0.31 5.82 0 
CD4 Microbeads mL 0 0.07 0 0.07 0 
CD3/28 Dynabeads Beads/mL 0 0 0 0 4.00×107 
Buffer mL 57 200 198 59 0 
Cell Culture Media mL 0 0 0 0 0 
Glucose g/mL 0 0 0 0 0 
Glutamine g/mL 0 0 0 0 0 
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Stream Name S-13 S-14 S-15 S-16 S-17 
Source  P-05  P-06 P-07 
Destination P-05 P-06 P-06 P-07  
Stream Properties Unit      
Temperature °C 23 23 23 23 23 
Pressure  Atm 1 1 1 1 1 
Component 
Volume mL 
1000 1,060.89 8940 10000.89 
0.89 
Red Blood Cell cells/mL 0 1.79×105 0 1.90×104 0 
White Blood Cell cells/mL 0 8.13×106 0 6.55×106 0 
Granulocytes cells/mL 0 4.30×104 0 4.56×103 0 
Monocytes cells/mL 0 7.74×104 0 8.21×103 0 
T-cell cells/mL 0 8.01×106 0 6.54×106 0 
Suppressor T-cell cells/mL 0 1.77×10-1 0 1.88×10-2 0 
Platelets cells/mL 0 1.93×107 0 2.05×106 0 
Plasma mL 0 5.82 0 5.82 0 
CD4 Microbeads mL 0 0 0 0 0 
CD3/28 Dynabeads beads/mL 0 3.77×104 0 4.00×103 4.00×103 
Buffer mL 0 59 0 59 0 
Cell Culture Media mL 1000 1000 8940 9940 0 
Glucose g/mL 1.00×10-3 8.58×10-4 1.00×10-3 8.58×10-4 0 
Glutamine g/mL 2.92×10-4 0 2.92×10-4  0 
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Stream Name S-18 S-19 S-20 
Source P-07 P-08 P-08 
Destination P-08  P-09 
Stream Properties Unit    
Temperature °C 23 23 23 
Pressure  Atm 1 1 1 
Volume mL 10000 9900 100 
Red Blood Cell cells/mL 1.90×104 1.73×104 1.90×105 
White Blood Cell cells/mL 6.55×106 6.62×105 5.90×108 
Granulocytes cells/mL 4.56×103 4.61×102 4.10×105 
Monocytes cells/mL 8.21×103 8.29×102 7.39×105 
T-cell cells/mL 6.54×106 6.61×105 5.89×105 
Suppressor T-cell cells/mL 1.88×10-2 1.90×10-3 1.69 
Platelets cells/mL 2.05×106 2.07×105 1.84×108 
Plasma mL 5.82 5.76 0.06 
CD4 Microbeads mL 0 0 0 
CD3/28 Dynabeads beads 0 0 0 
Buffer mL 59 44 15 
Cell Culture Media mL 9940 9805 135 
Glucose g/mL 1.41×10-4 1.44×10-4 1.67×10-4 
Glutamine g/mL 0 0 0 
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Chapter 5: Process description 
5.0: Blood collection in clinics (P-C2) 
 To collect T-cells, peripheral blood mononuclear (PBMC) concentrates are collected 
from an acute lymphoblastic leukemia patient using a blood cell separator (COBE® Spectra 
Apheresis System). A blood from a patient is continuously run through the cell separator 
machine and returned to the body until enough T-cell is collected for analysis. A total volume of 
8~12 L of whole blood is processed, and about 450mL of blood sample with the quantity of 
white blood cells between 5~20×109 cells is desired. The red blood cells, platelets, and the rest of 
the white blood cells are returned to the body. A collected blood is transferred either fresh (if it 
can be delivered within 4 hours) or frozen to adoptive t-cell therapy production facility (Clinical 
Cell and Vaccine Production Facility at Hospital of the University of Pennsylvania). 
 
5.1: Elutriation (P-02)  
 To separate red blood cells and white blood cells, the PBMC concentrate collection is 
processed with counter-flow elutriation instrument (Elutra® Cell Separating System, Terumo 
BCT) with a user-defined profile. A 450mL of patient’s PBMC concentrate will be mixed with 
elutriation buffer of 150 mL and go through counter-flow elutriation at 2400 RPMs and the 
media flow rate is maintained at 20mL/min for fraction 1 (high RBC concentration) and 
60mL/min for fraction 2 (high WBC concentration). The fraction 2 is collected and used for the 
next step. The fraction 1 and the cells remaining in the chamber are collected with the rotor off 
and disposed.  
 
5.2: Cell washing (P-03) 
 To wash cells for higher white blood cell purity, cells collected after the elutriation is 
washed out in a collection buffer in an automated cell-washing device (Cell Saver® 5+ 
Autologous Blood Recovery System). A centrifuge bowl size of 125ml is used with 750mL of a 
buffer solution at 4350 RPMs and media flow rate of 500mL/min.   
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5.3: Suppressor T-cell removal (P-04) 
 To remove regulatory (or suppressor) T-cell (CD4+), a magnetic extraction was 
performed using electromechenical cell separating device. (CliniMACS®). A removal of 
suppressor T-cell is desired because tumor cells in the body can block immune system upon 
recognizing suppressor t-cell, inhibiting t-cell immunotherapy to work efficiently.  The washed 
cells from Cell Saver are magnetically labeled using conjugated particle to anit-CD4 (CD4 
Microbeads, Miltenyi Biotec). A sterile, disposable tubing set is used to connect the bag 
containing the labeled cells to the device. The cell sample in a separation column under magnetic 
field separates out the labeled cells, undergoes several washing steps, and elutes the purified 
target cells (CD3/CD28).  
 
5.4: Cell culture in gas permeable bag (P-05) 
 To grow T-cells, purified target cells sample is cultured in a nutrient media with an 
addition of antibody-coated magnetic beads (Dynabeads® Human T-Activator CD3/CD28) and 
gene vectors for the stimulation of cell division and growth. The mixture of cells, magnetic 
beads, gene vectors, and growth media are added to a 1000mL gas-permeable plastic bag 
(MACS® GMP Cell Culture Bag). The cells are grown in a closed system to minimize the risk of 
contamination.  The cell suture is maintained in a gas permeable bag for 3-5 days. 
 
5.5: Cell expansion in bioreactor (P-06) 
 To expand T-cells further, the cell culture is transferred to a bioreactor (WAVE 
Bioreactor™ 2/10) during the log-phase cell growth. Cultures are maintained in a bioreactor for 
4-6 days. A total 4000mL of cell culturing media (CTS™ OpTmizer™ T Cell Expansion SFM) 
is fed over the period.   
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5.6: Dynabead removal (P-07) 
 To remove the magnetic dynabeads used to promote cell growth, a magnetic cell 
separator (MaxSEP® System) is used after the cell expansion and before the cell harvest.   
 
5.7: Cell harvest (P-08) 
 To collect the modified T-cells and remove other contaminants, an automated cell-
washing device (Cell Saver® 5+ Autologous Blood Recovery System) is used. The cell culture 
sample was processed at 4350RPMs at the flow rate of 1000mL/min for multiple washing cycles. 
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Chapter 6: Modeling 
6.0: Motivation 
 From talking to CCVP staff, we identified a critical step of the process that needed 
improvement. This was the elutriation that involves the Terumo Elutra®. The purpose of this 
step is to separate leukocytes (white blood cells) from erythrocytes (red blood cells). The 
leukocytes, which contain the desired T-cells must be rid of erythrocytes. If allowed to remain in 
the cell mixture, cell processing protocols in following steps will cause red blood cells to lyse, 
releasing their toxic contents into the overall mixture. This kills the T-cells of interest, either 
lengthening the following cell culture steps or causing the operation to fail outright. Accordingly, 
this step of the procedure is crucial. Though elutriation typically has a high success rate, the 
separation is less effective for blood samples that have low leukocyte counts to start with, which 
is not uncommon considering the fact that these patients are immune-compromised to begin 
with. 
 In this section, we develop a model for the separation of erythrocytes from leukocytes. 
Currently, the CCVP is using the same protocol for each different patient, which leads to failure 
in patients with low leukocyte counts. Based on second-hand sources, we predict the current 
failure rate to be 10%. By modeling the elutriation process, we hope to gain insight on how 
various parameters affect the difference in average residence times between leukocytes and 
erythrocytes. Using the model, we will make a recommendation on an optimized operating 
protocol for the removal of erythrocytes from the cell mixture. We predict that optimizing the 
protocol will result in a reduction of the failure rate from 10% to 1%. This is significant not only 
in its economic implications. A successful separation could mean the difference between life and 
death for a suffering patient. 
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6.1: Theoretical background 
 Counterflow centrifugal elutriation (CCE) is the technique that the Terumo Elutra® uses 
for its separation, and it is the technique which we base our model. CCE separates particles based 
on both size and density. Figure 6.1A schematically illustrates CCE. Blood cells are pumped 
through the chamber from outside to inside while the chamber spins around. This applies two 
opposing forces on particles within the fluid, a drag force that pushes particles through the 
chamber and a centrifugal force that opposes movement of the particle through the chamber (see 
Figure 6.1B). 
 
 
 
 
 Theoretical estimates for the forces on the particle were performed by Morijiri et al.1 The 
centrifugal force, Fc is expressed by Equation 1. 
𝐹𝑐 =
𝜋
6
𝐷𝑝
3(𝜌𝑝 − 𝜌𝑓)𝑟𝜔
2 
Where Fc = centrifugal force 
            Dp = particle diameter 
            ρp = particle density 
            ρf = fluid density 
            r = distance from axis of rotation 
            ω = angular velocity 
  
  
A B 
Fd Fc 
Figure 6. 4: A) Schematic for counterflow centrifugal elutriation. B) Force balance on a particle inside the chamber. 
Equation 1 
Q 
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The fluid drag force, Fd is approximately given by Equation 2 for small Reynolds number 
(Re < 1).  
𝐹𝑑 = 3𝜋𝜇𝐷𝑝𝑈{𝑟} = 3𝜋𝜇𝐷𝑝(𝑈𝑓{𝑟} − 𝑈𝑝{𝑟}) 
Where Fd = fluid drag force 
            μ = fluid viscosity 
            U{r} = relative particle flow velocity at r 
            Uf{r} = average flow velocity at r 
            Up{r} = particle flow velocity at r  
𝑈𝑓{𝑟} =
𝑄
𝑆{𝑟}
 
Where Q = volumetric flow rate through chamber 
            S{r} = cross-sectional area of chamber at r 
 
6.2: Determination of cell dimensions 
 From literature, we found physical dimensions for leukocytes and erythrocytes.1 These 
are given in table 6.1. Leukocytes are spherical, so their dimensions are rather straightforward 
for the purposes of the model; however, erythrocytes are disk-shaped. Thus, we need to reduce 
these cells to a sphere and calculate an effective diameter. 
Table 6.1: Dimensions of erythrocytes and leukocytes 
Cell Type Density (g/cm3) Shape Diameter (μm) Thickness (μm) 
Erythrocytes 1.10 Disk 7 2 
Leukocytes 1.07 Sphere 12 NA 
 
  
Equation 2 
Equation 3 
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To calculate an average effective diameter for erythrocytes, we used a method described 
by Li et al. to calculate effective diameter of non-spherical particles in a packed bed reactor.2 
Sphericity of erythrocytes was first calculated. This is detailed by Equation 4. For the case of 
disk-shaped erythrocytes with dimensions detailed by table 6.1, the sphericity was calculated as 
0.723. See the sample calculations section for a more details. 
𝜑 =
𝑠𝑢𝑟𝑓𝑎𝑐𝑒 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑠𝑝ℎ𝑒𝑟𝑒 𝑜𝑓 𝑒𝑞𝑢𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑡𝑜 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒
𝑠𝑢𝑟𝑓𝑎𝑐𝑒 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒
 
 The Sauter mean diameter (dsd) is also required to calculate the effective diameter. This is 
defined by Equation 5. For erythrocytes, the value was calculated as 3.82 μm. Finally, the 
effective diameter is defined by Equation 6, and this is simply the product of the Sauter mean 
diameter and sphericity. For erythrocytes, the effective diameter was calculated to be 2.76 μm. 
See Appendix B for detailed calculations. Table 6.2 gives the new cell dimensions that will be 
used in the model. 
𝑑𝑠𝑑 =
6𝑉𝑝
𝐴𝑝
 
Where dsd = Sauter mean diameter 
            Vp = volume of particle 
            Ap = surface area of particle 
𝑑𝑒𝑓𝑓 = 𝜑𝑑𝑠𝑑 
Where deff = effective diameter 
 
Table 6.2: Modified cell dimensions table 
Cell Type Effective Diameter (μm) Density (kg/m3) Mass (kg) 
Erythrocytes 2.76 1100 1.21*10-14 
Leukocytes 12 1070 9.68*10-13 
  
Equation 4 
Equation 5 
Equation 6 
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6.3: Solving for particle movement in the chamber 
 To solve for particle movement in the chamber versus time, we performed a force 
balance on a single particle in the chamber. This is shown by Equation 7. Algebraic 
rearrangement of Equation 7, combined with the identities of Equation 8 and Equation 9 result in 
an ordinary differential equation (Equation 10).  
𝐹𝑛𝑒𝑡 = 𝐹𝑐 − 𝐹𝑑 = 𝑚𝑝𝑎𝑝 
𝑈𝑝{𝑟} =
𝑑𝑟
𝑑𝑡
 
𝑎𝑝 =
𝑑2𝑟
𝑑𝑡2
 
𝑚𝑝
𝑑2𝑟
𝑑𝑡2
− 3𝜋𝜇𝐷𝑝
𝑑𝑟
𝑑𝑡
−
𝜋
6
𝐷𝑝
3𝜔2(𝜌𝑝 − 𝜌𝑓)𝑟 + 3𝜋𝜇𝐷𝑝𝑈𝑓{𝑟} = 0 
 
Figure 6.5: Diagram of cell separator chamber dimensions 
  
Equation 7 
Equation 8 
Equation 9 
Equation 10 
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6.4: Solving for residence time in a tube 
 Because Uf{r} is a function of radius in the above geometry, we decided to simplify the 
problem and solve for the average residence time in a tube geometry. By setting the separation 
chamber as a tube, the average fluid flow velocity becomes a constant. To solve for Uf in this 
specific geometry, this is the flow rate divided by the cross-sectional area of the tube. 
 
Figure 6.6: Diagram of tube cell CCE 
 With Uf as a constant, the governing equation (Equation 15) becomes a linear ordinary 
differential equation. Constants were lumped, and Equation 15 was shown in the simplified form 
shown in Equation 16.  
𝑑2𝑟
𝑑𝑡2
− 𝐴
𝑑𝑟
𝑑𝑡
+ 𝐵𝑟 + 𝐶 = 0 
Where A = 
3𝜋𝜇𝐷𝑝
𝑚𝑝
 
            B = 
𝜋
6
𝐷𝑝
3(𝜌𝑝−𝜌𝑓)𝜔
2
𝑚𝑝
 
            C = 
3𝜋𝜇𝐷𝑝𝑈𝑓
𝑚𝑝
 
  
Equation 16 
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 To solve for the residence time, Equation 16 was solved using the ODE45 function in 
Matlab (see Appendix C). Some standard operating parameters for the elutriation were then 
defined from comparable values from literature. These standard operating parameters are shown 
in table 6.3. The elutriation buffer fluid was assumed to have the same properties as those of 
water. Also, the chamber volume was set to a standard value of 4 mL,3 the rotation frequency 
was set to 2400 rotations per minute, and the fluid volumetric flow rate was set as 100 mL/min.4 
Initial particle position was set at Ri, and initial particle velocity was set as zero. 
Table 6.3: Standard operating parameters for counterflow centrifugal elutriation 
Parameter Value Units 
μ 6.53*10-4 𝑁
𝑠
𝑚2
 
ρf 1000 𝑘𝑔
𝑚3
 
ω 251 𝑟𝑎𝑑
𝑠
 
D 0.00714 m 
R 0.152 m 
Ro 0.102 m 
Ri 0.202 m 
Q -1.67*10-6 𝑚3
𝑠
 
Uf -4.18*10-2 𝑚
𝑠
 
 
Plugging the properties of erythrocytes from table 6.2 and the defined standard operating 
parameters into Matlab resulted in the graphs shown in figure 6.4 and figure 6.5. From figure 
6.4, the average residence time is 2.4 seconds. Figure 6.5 shows that the terminal velocity is 
reached very quickly at which point the decrease in centrifugal force slowly decreases. Figure 
6.6 and figure 6.7 show comparable graphs for leukocytes at standard operating conditions. 
Figure 6.6 shows that the residence time is 3.0 seconds, about half a second more than that of 
erythrocytes. This tells us that the release of erythrocytes and leukocytes likely overlap, 
suggesting poor separation. Figure 6.7 shows that leukocytes experience a greater increase in 
terminal velocity due to the decrease in centrifugal force. Various parameters will now be 
manipulated to maximize the difference in residence times. 
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Figure 6.7: Displacement vs. time of erythrocyte at standard operating conditions 
 
Figure 6.8: Velocity vs. time of erythrocytes at standard operating conditions 
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Figure 6.9: Displacement vs. time of leukocytes at standard operating conditions 
 
Figure 6.10: Velocity vs. time of leukocytes at standard operating conditions 
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6.5: Effect of changing the elutriation buffer density 
 First, we looked at the effect of changing the elutriation buffer density on the residence 
times of leukocytes and erythrocytes. Practically, this can be done by adding salts to the 
elutriation buffer solution or changing temperature and pressure of the fluid. We varied fluid 
density from 900 kg/m3 to 1400 kg/m3. Although the higher buffer densities are not practical 
because such a high salt concentration would cause cells to shrivel, we were interested in 
exploring a wide range of densities to see the effect on residence times. The Matlab solutions 
indicated that as the elutriation buffer density increased, the residence times decreased. Table 6.3 
shows the residence times versus elutriation buffer densities.  
 Interestingly, the leukocyte residence times start out higher than the erythrocyte residence 
times, but at a buffer density between 1050 and 1100 kg/m3, leukocyte residence times become 
lower than erythrocyte residence times. This implies that by changing the buffer fluid density, we 
can change the overall order of elutriation. Also, when the elutriation buffer density was 
increased above the density of the particles, the terminal velocity started decreasing in magnitude 
as the particle moved through the chamber. This is due to the centrifugal force (term B in 
Equation 10) reversing its magnitude once ρf - ρp reverses in magnitude. Figure 6.8 is a graph 
showing the results of table 6.3. 
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Table 6.4: Table showing the effect of varying elutriation buffer density on residence times 
ρf (kg/m3) Erythrocyte 
residence times (s) 
Leukocyte 
residence times (s) 
Difference in 
residence times (s) 
900 2.46 4.72 2.26 
950 2.45 3.64 1.19 
1000 (nominal) 2.43 2.98 0.55 
1050 2.41 2.54 0.13 
1100 2.39 2.21 0.18 
1150 2.38 1.96 0.42 
1200 2.36 1.76 0.6 
1250 2.34 1.6 0.74 
1300 2.32 1.46 0.86 
1350 2.31 1.35 0.96 
1400 2.29 1.25 1.04 
  
 
Figure 6.11: Graph of elutriation buffer density versus residence time of leukocytes and 
erythrocytes. The erythrocyte residence times remain relatively constant, while the leukocyte 
residence times decrease as the buffer density increases. At a point between 1050 and 1100 kg/m3, 
the average residence time for leukocytes drops below that of erythrocytes, suggesting that the order 
of elution can be changed by changing the buffer density. 
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6.6: Effect of changing the elutriation buffer viscosity 
 We also looked at the effect of elutriation buffer viscosity on residence time. Similar to 
modifying the fluid density, this can be performed by adding solutes to the buffer. We modified 
the viscosity from 2.5*10-4 to 2.05*10-3 N*s/m2. What we found was that as the buffer viscosity 
increased, the leukocyte residence time decreased, while the erythrocyte residence times did not 
change very much. Table 6.5 and figure 6.9 show how the residence times were affected by 
changes in viscosity. The best separations occurred when buffer viscosity was the lowest. 
 
Table 6.5: Table showing the effect of varying elutriation buffer viscosity on residence times 
μ (N*s/m2) Erythrocyte 
residence times (s) 
Leukocyte 
residence time (s) 
Difference in 
residence times (s) 
2.50E-04 2.49 5.13 2.64 
4.50E-04 2.45 3.37 0.92 
6.50E-04 (nominal) 2.43 2.98 0.55 
8.50E-04 2.42 2.82 0.4 
1.05E-03 2.42 2.73 0.31 
1.25E-03 2.41 2.67 0.26 
1.45E-03 2.41 2.63 0.22 
1.65E-03 2.41 2.6 0.19 
1.85E-03 2.41 2.57 0.16 
2.05E-03 2.41 2.55 0.14 
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Figure 6.12: Graph of elutriation buffer viscosity versus residence time of leukocytes and erythrocytes. As the viscosity 
increases, the leukocyte residence time decreases, asymptotically approaching the residence time of erythrocytes. This 
suggests that the best separations occur at low fluid viscosities. 
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6.7: Effect of changing the chamber rotation frequency 
 The chamber rotation frequency was the next parameter we looked at. We varied the 
frequency from zero to 450 radians per second. The nominal frequency of 250 corresponds to the 
2400 rotations per minute that is currently used at the CCVP. Table 6.6 and figure 6.10 show the 
results of varying the chamber rotation frequency on the average residence times of leukocytes and 
erythrocytes. As the rotation frequency increased, the difference in residence times increased 
exponentially. Interestingly, without any rotation, the difference in the residence times is zero, which 
illustrates the importance of the rotation on separation of particles. 
 
Table 6.6: Table showing the effect of varying chamber rotation frequency on residence times 
ω (s-1) Erythrocyte 
residence times (s) 
Leukocyte 
residence times (s) 
Difference in 
residence times (s) 
0 2.39 2.39 0 
50 2.39 2.41 0.02 
100 2.4 2.47 0.07 
150 2.41 2.57 0.16 
200 2.42 2.74 0.32 
250 (nominal) 2.43 2.98 0.55 
300 2.45 3.34 0.89 
350 2.46 3.93 1.47 
400 2.49 4.96 2.47 
450 2.51 7.35 4.84 
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Figure 6.13: Graph of chamber rotation frequency versus residence time of leukocytes and erythrocytes. The 
difference between residence times start off the same at low chamber rotations, but as the rotation frequency 
increases, the difference in residence times increase as well. This suggests that better separations occur at higher 
rotation frequencies. 
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6.8: Effect of changing the chamber distance from the axis of rotation 
 The distance of the center of the chamber from the axis of rotation was another 
parameter that we looked at. We varied the distance from 0.052 meters to 0.252 meters. 
The effect of chamber distance on residence times is shown in table 6.7 and figure 6.11. 
Results were very similar to the results of the chamber rotation frequency tests. As the 
chamber distance increased, the difference in residence times increased. This makes 
sense because increasing the chamber distance increases the centrifugal force term (3rd 
term in Equation 16). 
Table 6.7: Table showing the effect of varying chamber distance on residence times 
R (m) Erythrocyte 
residence times (s) 
Leukocyte 
residence times (s) 
Difference in 
residence times (s) 
0.052 2.41 2.57 0.16 
0.102 2.42 2.76 0.34 
0.152 (nominal) 2.43 2.98 0.55 
0.202 2.44 3.24 0.8 
0.252 2.45 3.55 1.1 
 
 
Figure 6.14: Graph of chamber distance versus residence time of leukocytes and erythrocytes. As the distance from the 
axis of rotation increases, the difference in residence times increases as well. 
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6.9: Effect of changing elutriation buffer flowrate 
 Finally, we looked at how changing the flowrate of the elutriation buffer affected the 
residence times of the leukocytes and erythrocytes. Elutriation buffer flowrate was varied from 
40 to 140 mL/min. The results of these trials are found in table 6.8 and figure 6.12. As the 
flowrate of buffer increased, the difference in residence times decreased. This suggests that the 
best separations occur at low flowrates. 
Table 6.8: Table showing the effect of varying elutriation buffer flowrate on residence times 
Q (mL/min) Erythrocytes 
residences times (s) 
Leukocyte 
residence times (s) 
Difference in 
residence times (s) 
40 6.24 12.2 5.96 
60 4.11 6.02 1.91 
80 3.07 4.02 0.95 
100 (nominal) 2.43 2.98 0.55 
120 2.03 2.4 0.37 
140 1.74 2 0.26 
 
 
Figure 6.15: Graph of elutriation buffer flowrate versus residence time of leukocytes and erythrocytes. As the buffer 
flowrate increases, the difference in residence times decreases. This suggests that better separations occur at low 
flowrates. 
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6.10: Determining the optimal operating protocol 
 From the previous modeling trials, we were able to determine a set of conditions to 
optimally operate counterflow centrifugal elutriation (CCE). We decided to vary the elutriation 
buffer flowrate and keep the rest of the parameters at standard operating conditions. Two settings 
are to be used, a low flowrate setting where the red blood cells are eluted followed by a high 
flowrate setting where the remaining leukocytes are eluted. Our model determined that 20 
mL/min was a key flowrate. At this flowrate, erythrocytes flowed through the chamber with an 
average residence time of 13 seconds, as shown by figure 6.13 and figure 6.14. In contrast, figure 
6.15 and figure 6.16 show that leukocytes become held up within the chamber. This is indicated 
by the positive values for displacement and velocity. The positive values mean that the 
leukocytes will remain at the chamber inlet while the erythrocytes will be eluted. Once the 
erythrocytes have been eluted, the buffer flowrate will be increased to 60 mL/min. At this 
flowrate, the remaining leukocytes should be eluted with an average residence time of six 
seconds (table 6.8). Thus, the CCE should first be run at 20 mL/min for a minute, then the CCE 
should be run at 60 mL/min for a minute to achieve the best separation between leukocytes and 
erythrocytes. 
 In summary, by modeling counterflow centrifugal elutriation, we determined a protocol 
that would increase the efficiency of separation between erythrocytes and leukocytes. This would 
help to decrease the failure rate of the procedure, which would increase the profitability of the 
overall process. The effect of this modification will be analyzed in the following profitability 
analysis. 
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Figure 6.16: Displacement versus time for erythrocytes at a flowrate of 20 mL/min 
 
Figure 6.17: Velocity versus time for erythrocytes at a flowrate of 20 mL/min 
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Figure 6.18: Displacement versus time for leukocytes at a flowrate of 20 mL/min 
 
Figure 6.19: Velocity versus time for leukocytes at a flowrate of 20 mL/min 
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Chapter 7: Unit descriptions 
7.0: Major unit descriptions 
7.0.0: COBE Spectra (PC-2) 
 A COBE Spectra Apheresis System is a commonly used therapeutic apheresis machine 
that allows high degree of customization. It uses a centrifugal technology to divide the whole 
blood into its major components. When the blood sample is collected from the patient in one of 
the clinics, a blood from a patient is continuously running through the machine, specific 
components are collected or removed from the sample, and the remaining components are 
returned to the patient. A total of 8 to 12 liters of whole blood is processed until at least 5×109 
white blood cells are collected. The vendor of the product is TerumoBCT. 
 
7.0.1: Elutra® (P-02) 
 An Elutra® Cell Separating System is a semi-automatic counter-flow elutriation 
instrument with multiple user-defined profiles, and it can separate a blood sample into multiple 
fractions according to the size of cell components. A counter-flow centrifugal elutriation 
technology is used, in which a centrifugal force is applied opposite to the flow direction of 
media. While the chamber is rotated in a centrifuge, cells are loaded into a chamber at a flow 
rate. When the flow rate is changed, the cell components are separated and come out through the 
chamber by their sizes, smaller components first. We will process 450 ml of blood sample mixed 
with 150mL of buffer solution at 20mL/min for 1 minute and 60mL/min for 1 minute at 2400 
RPM for optimal separation of red blood cells from the white blood cells. The device can be 
purchased from Terumo BCT® for $55,000. 
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7.0.2: Cell Saver® 5+ (P-03, P-08) 
 A Cell Saver® 5+ Autologous Blood Recovery System is a blood recovery system using 
Latham bowl centrifuge technology invented by Haemonetics. Latham bowl technology uses 
centrifugal forces to separate red blood cells, white blood cells, and plasma and platelets by their 
weights. After elutriation, a Cell Saver is used to wash out remaining platelets and some red 
blood cells in the sample to increase white blood cell purity. After cell culture and expansion, 
Cell Saver is used to reduce volume of the sample and increase purity of t cell by removing gene 
vectors and media waste. The device can be purchased from Haemonetics® for $18,500. 
7.0.3: CliniMACS® (P-04) 
 A CliniMACS® is an electromechanical device for isolating specific cells via magnetic 
force in a closed and sterile system. A magnetic microbeads are used to label suppressor T cell 
(CD4+). A magnetic field is applied to remove suppressor t cell, and the remaining sample is 
washed out with buffer and elutriated. 
 
7.0.4: Gas permeable bag (P-05) 
 A MACS® GMP Cell Culture Bag is a cell culturing bag that is gas-permeable and 
transparent for microscopic analysis. The bag is for single use and is sterile for connections. A 
60ml of the cell concentrates are cultured with 1000mL of t-cell culture media for 3 to 5 days in 
a stationary bag.  
 
7.0.5: WAVE Bioreactor™ 2/10 (P-06) 
 A WAVE Bioreactor™ 10/20 is a cell culturing instrument. A culture medium and the 
cell sample are loaded into a single-use, sterile Cellbag, and the Cellbag is placed on a rocking 
motion. The rocking motion induces a wave within the fluid, which provides efficient mixing 
and gas transfer. A cell culture from the gas permeable bag is transferred to a WAVE Bioreactor 
for further expansion of T cell.  
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7.0.6: MaxSep (P-07) 
 MaxSEP® Magnetic Cell Separator is used to remove the CD3/28 dynabeads that are 
within the cell culture. The MaxSEP consists of a tray with strong magnet imbedded underneath. 
When a bag filled with the dynabeads is placed on tray, the beads stick to the tray and media can 
then be removed from the bag. After all media has been disposed of, the magnet in the tray can 
be turned off and the beads will be released for disposal.  
 
7.1: Additional equipment descriptions 
 
7.1.0: Ventilation systems 
 A ventilation system is required for a facility to ensure biosafety and sanitation. A 
handling of the blood samples and biomass should be under the bench with a ventilation hood. A 
ventilation hood will be required for each of the cell processing room and media preparation 
room. A 4-ft and 6-ft laminar flow hood can be purchased from Air Science for $1,000 and 
$1,600 respectively. For the entire facility, 10 4-ft laminar flow hood and 24 6-ft laminar flow 
hood is desired. Air particles in the ventilation system are monitored by an air particle samplers 
and counters. Four total air particle counters can be purchased from Lighthouse for $1000 each, 
and 2 viable air particle samplers can be purchased from Beckman Coulter® for $1700 each. 
 
7.1.1: Incubators 
 Incubators are used to maintain optimal conditions for the cell cultures while they are in 
the cell processing rooms. A desired temperature and carbon dioxide concentration can be set 
and maintained. For the entire facility, 34 HEPA filtered CO2 Incubators can be purchased from 
Sanyo for $1,500 per device and 4 table-top CO2 Incubators can be purchased from Sanyo® for 
$5,000 per device.  
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7.1.2: Centrifuges 
 The centrifuges are used in various occasions to spin down cell cultures or samples. Two 
small capacity (4x145mL), bench-top centrifuges, SorvallTM Biofuge PrimeTM R Benchtop 
centrifuges, can be purchased for $3381 per device, 22 medium-capacity (4 x 750ml) bench top 
centrifuges, SorvallTM LegendTM RT Centrifuges for $8774 per device, and 4 large-capacity (6 x 
1400mL) centrifuges, SorvallTM RC-3B Plus High Capacity Centrifuge, can be purchased for 
$5000 per device, all from Thermo Scientific®. These centrifuges can be refrigerated as needed. 
For smaller volume, microcentrifuges can be used. Total 22 microcentrifuges, LSE™ Mini 
Microcentrifuge, can be purchased from Corning® for $300 per device.  
 
7.1.3: Refrigeration 
 A liquid nitrogen freezer is used to store the cells. For the entire facility, 22 liquid 
nitrogen freezers can be purchased for $25,000 per device from LABRepco®. A liquid nitrogen 
manifold changeover, which controls the amount of liquid nitrogen distributed to the freezers 
from the tank, can be purchased from Airgas for $3353 per device. Additionally, a controlled rate 
freezer is required to ensure cell viability for low temperature freezing. A controlled rate freezer 
can be purchased from True® for $20336, and 10 freezers are needed. 
 A -30°C, -40°C, -80°C freezers are needed for storage of some materials and samples. 
For the entire facility, six -30°C freezers, two -40°C freezers, and eight -80°C freezers will be 
purchased from True® for $9500 each.  
 Most of the materials including buffer solutions, media, and reagents will be stored in a 
refrigerator. Different kinds of refrigerator will be installed based on the needs and location in 
the facility. Total 28 under-counter refrigerators will be purchased from Avanti® for $700 each, 
10 double door refrigerators from Custom Biogenic systems for $400 each, 4 upright 
refrigerators and 2 refrigerator and freezer combos from Kenmore® for $300 and $200 each, and 
4 chromatography refrigerators from Thermo Scientific® for $6625 each. 
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7.1.4: Flow cytometer & cell counter 
 The number of cells in the sample for each step and during the cell growth and expansion 
are measured using flow cytometers and cell counters. Two LSRFortessaTM and two 
FACSCaliburTM can be purchased from BD Biosciences for $1165 and $29500 per device.  
A MultisizerTM 3 Coulter Counter device can be purchased from Beckman Coulter® for $5000 
and the device can measure the number, volume, mass, and surface size distributions in one 
measurement. Total 8 units of the device will be purchased.  
 
7.1.5: Blood culturing system 
 A blood culturing system is a very precise instrument for detecting biological growth 
within a sample of blood. This is essential when monitoring the growing cells in the bioreactor. 
A blood culturing system from BACTEC can be purchased for $21,105.  
 
7.1.6: Digital balance  
 Digital balances are used throughout the process to precisely measure out various 
materials used. Mass precision is extremely important when handing media and the growth of 
cells. While there are many providers of this commonly used equipment, a high quality scale can 
be purchased form Taylor for $200.  
 
7.1.7: Luminometer  
 A luminometer is a device that is capable of emitting and registering radiation over a 
broad range of frequencies. These are useful in conducting assays of growth media as the cells 
are being expanded. A luminometer may be purchased from Promega for $80.  
 
7.1.8: Microscope  
 Microscopes are required for various steps of the process to observe the growing cells 
and monitor for any irregularities in the process. A common vendor of microscopes is AmScope, 
where a suitable one may be purchased for $350.   
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7.1.9: Spectrophotometer 
 A spectrophotometer is used to analyze the nucleic acid and protein concentrations of the 
cell sample. The device can be purchased from Thermo Scientific® for $10,000.  
 
7.1.10: Plate washer 
 A plate washer is used to wash cells and beads that reside on the plate. Two plate washers 
are needed and they can be purchased from Tecan® for $1000. 
 
7.1.11: Tube connection 
 A disposable tubing system is used in different machines in the facility, and a sterile 
procedure is required. A SebraHeat Sealer, which seals the tubes that are cut, can be purchased 
from Haemonetics for $5400 each, and 44 units are needed. A sterile connecting device that 
connects two tubes can be purchased from Terumo BCT® for $1500, and 30 units are needed. 
 
7.1.12: Water bath 
 A water bath is used to warm up media or other reagents used for a cell culture. It can be 
purchased from Thermo Scientific for $150, and 34 units are needed.  
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Chapter 8: Unit specification sheets  
8.0: COBE Spectra (P-C2) 
COBE® Spectra Apheresis System 
Description and Function A blood cell separator 
To separate blood cells based on cell density and size 
Manufacturer Terumo BCT 
PFD Reference P-C2 
Operation Batch 
Materials Handled  Unit Input  Output 
(to lab) 
Output  
(to Patient) 
Red Blood Cell cells/mL 5.20×109 4.44×108 5.42×109 
White Blood Cell cells/mL 7.50×106 3.33×107 6.29×106 
Granulocytes cells/mL 9.07×105 4.02×106 7.60×105 
Monocytes cells/mL 1.57×106 6.98×106 1.32×106 
T- cell cells/mL 4.99×106 2.22×107 4.19×106 
Suppressor T-cell cells/mL 2.51×104 1.11×105 2.10×104 
Platelets cells/mL 3.50×108 1.04×109 3.17×108 
Plasma mL 5430 244.35 5185.65 
Characteristics Dimension 148cm (H) x 70cm (W) x 71cm (D) 
Weight 177kg 
Operating Conditions Temperature Room temperature 
Pressure 1 atm 
Duration 2-4 hours 
Flow Rate 0-150 mL/min 
Centrifuge Speed 400-2400 rpm 
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8.1: Elutra® Cell Separating System (P-02) 
Elutra® Cell Separating System 
Description and 
Function 
Counter-flow elutriation based on cell density and size 
To separates leukocytes from the blood sample 
Manufacturer Terumo BCT 
PFD Reference P-02 
Operation Batch 
Materials Handled  Unit Input  Waste  Output  
Red Blood Cell cells/mL 3.33×108 3.67×108 3.33×107 
White Blood Cell cells/mL 2.50×107 1.85×107 8.27×107 
Granulocytes cells/mL 3.02×106 3.17×106 1.67×106 
Monocytes cells/mL 5.23×106 5.48×106 3.00×106 
T- cell cells/mL 1.66×107 9.80×106 7.80×107 
Suppressor T-cell cells/mL 8.33×104 9.25×104 1.30×103 
Platelets cells/mL 7.83×108 6.48×108 2.00×109 
Plasma mL 244.35 219.92 24.44 
Buffer mL 150 0 0 
Characteristics Model Elutra® Cell Separating System 
Dimension 180.3cm (H) x 70cm (W) x 68cm (D) 
Weight 177kg 
Operating 
Conditions 
Temperature Room temperature 
Pressure 1 atm 
Duration 1-2 hours 
Flow Rate 0-120 mL/min 
Centrifuge Speed 0-2400 rpm 
Purchase Cost $55,000 
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8.2: Cell Saver 5+ (P-03, P-08) 
Cell Saver® 5+ Autologous Blood Recovery System 
Description and 
Function 
A cell-washing machine  
To wash blood sample to increase purity or reduce volume 
Manufacturer Haemonetics® 
PFD Reference P-03, P-08 
Operation Batch 
Materials Handled  Unit Input  Waste  Output  
Red Blood Cell cells/mL 3.33×107 2.40×106 3.33×106 
White Blood Cell cells/mL 8.27×107 3.44×106 3.97×107 
Granulocytes cells/mL 1.67×106 6.93×104 8.00×105 
Monocytes cells/mL 3.00×106 1.25×105 1.44×106 
T- cell cells/mL 7.80×107 3.24×106 3.74×107 
Suppressor T-cell cells/mL 1.30×103 2.71×101 3.13×102 
Platelets cells/mL 2.00×109 1.31×108 3.59×108 
Plasma mL 24.44 18.31 6.12 
Buffer mL 750 693 57 
Characteristics Model Cell Saver® 5+ Autologous Blood 
Recovery System 
Dimension 94cm (H) x 40.6cm (W) x 36.8cm 
(D) 
Weight 32.2kg (machine), 15.9kg (cart) 
Operating 
Conditions 
Temperature Room Temperature 
Pressure 1 atm 
Flow Rate 0-1000 mL/min 
Centrifuge Speed 2050-5650 rpm 
Purchase Cost $18,500 
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8.3: CliniMACS (P-04) 
CliniMACS® Plus Instrument 
Description and 
Function 
 A magnetic cell isolation machine 
 To remove suppressor t-cell  
Manufacturer Miltenyi Biotec 
PFD Reference P-04 
Operation Batch 
Materials Handled  Unit Input  Waste  Output  
Red Blood Cell cells/mL 60 5.00×104 3.17×106 
White Blood Cell cells/mL 3.33×106 5.95×105 3.77×107 
Granulocytes cells/mL 3.97×107 1.20×104 7.60×105 
Monocytes cells/mL 8.00×105 2.16×104 1.37×106 
T- cell cells/mL 1.44×106 5.62×106 3.56×107 
Suppressor T-cell cells/mL 3.74×107 9.29×101 3.13 
Platelets cells/mL 3.13×102 5.39×106 3.23×108 
Plasma mL 3.59×108 0.31 5.82 
CD4 Microbeads mL 0.07 0 0.07 
Buffer mL 257 198 59 
Characteristics Model CS2-CE/UL 
Dimension 70cm (H) x 90cm (W) x 60cm (D) 
Weight 35kg 
Operating Conditions Temperature Room Temperature 
Pressure 1 atm 
Duration 2-6 hours 
Purchase Cost $55,000 
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8.4: Gas Permeable Bag (P-05) 
MACS®GMP Cell Differentiation Bag 
Description and 
Function 
A gas permeable bag 
To grow cell culture 
Manufacturer Miltenyi Biotec 
PFD Reference P-05 
Operation Batch 
Materials Handled  Unit Input   Output  
Red Blood Cell cells/mL 3.17×106 1.79×105 
White Blood Cell cells/mL 3.77×107 8.13×106 
Granulocytes cells/mL 7.60×105 4.30×104 
Monocytes cells/mL 1.37×106 7.74×104 
T- cell cells/mL 3.56×107 8.01×106 
Suppressor T-cell cells/mL 3.13 1.77×10-1 
Platelets cells/mL 3.23×108 1.93×107 
Plasma mL 5.82 5.82 
CD3/28 Dynabeads beads /mL 4.00×107 3.77×104 
Buffer mL 59 59 
Culture media mL 1000 1000 
Characteristics Model REF 170-076-404 
Capacity (Volume) 1000mL 
Operating Conditions Temperature 37°C 
Pressure 1 atm 
Duration 3~5 Days 
Purchase Cost $76 
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8.5: Wave Bioreactor 2/10 (P-06) 
WAVE Bioreactor TM 2/10 
Description and 
Function 
A wave-rocking bioreactor 
To expand cell culture 
Manufacturer GE Healthcare Life Sciences 
PFD Reference P-06 
Operation Batch 
Materials Handled  Unit Input   Output  
Red Blood Cell cells/mL 1.79×105 1.90×104 
White Blood Cell cells/mL 8.13×106 6.55×106 
Granulocytes cells/mL 4.30×104 4.56×103 
Monocytes cells/mL 7.74×104 8.21×103 
T- cell cells/mL 8.01×106 6.54×106 
Suppressor T-cell cells/mL 1.77×10-1 1.88×10-2 
Platelets cells/mL 1.93×107 2.05×106 
Plasma mL 5.82 5.82 
CD3/28 Dynabeads beads /mL 3.77×104 4.00×103 
Buffer mL 59 59 
Culture media mL 9940 9940 
Characteristics Model WAVE Bioreactor TM 2/10 
Capacity (Volume) 10L 
Operating Conditions Temperature 37°C 
Pressure 1 atm 
Duration 4~6 Days 
Purchase Cost $47,500 
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8.6: MaxSep (P-07) 
MaxSEP Magnetic Cell Separator 
Description and 
Function 
A magnetic separator 
To remove dynabeads from the cell culture 
Manufacturer Baxter Fenwal 
PFD Reference P-07 
Operation Batch 
Materials Handled  Unit Input  Waste  Output  
Red Blood Cell cells/mL 1.90×104 0 1.90×104 
White Blood 
Cell 
cells/mL 
6.55×106 0 6.55×106 
Granulocytes cells/mL 4.56×103 0 4.56×103 
Monocytes cells/mL 8.21×103 0 8.21×103 
T- cell cells/mL 6.54×106 0 6.54×106 
Suppressor T-
cell 
cells/mL 
1.88×10-2 0 1.88×10-2 
Platelets cells/mL 2.05×106 0 2.05×106 
Plasma mL 5.82 0 5.82 
CD3/28 
Dynabeads 
beads 
/mL 
4.00×103 4.00×103 
0 
Buffer mL 59 0 59 
Culture media mL 9940 0 9940 
Characteristics Model MaxSEP Magnetic Cell Separator 
Operating Conditions Temperature Room Temperature 
Pressure 1 atm 
Purchase Cost $1,165 
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Chapter 9: Overall process cost for T-cell therapy 
9.0: Utility costs 
The primary utilities required for operating most chemical or pharmaceutical plants are 
water and electricity. The requirement for water in this process is minimal, as most fluids used in 
the process are sterile media or buffers. There is no requirement for cooling water as 
temperatures for most of the process stay close to body temperature. Samples are typically cryo-
preserved immediately upon completion of the process, but this is a short process that mainly 
requires careful storage of liquid nitrogen.  
 The cost of electricity for the process is negligible. Not requiring large columns or other 
equipment, as well as the lack of any extremely high temperatures or pressures, significantly 
reduces the energy requirement. The Wave Bioreactors used in expanding the cells would require 
the most energy as it is the piece of equipment that is run almost continuously for the majority of 
the process. However a single WAVE Bioreactor System 2/10, with a power rating of 87W, 
would cost $43.85 to continuously operate for an entire working year. This is assuming a cost of 
electricity at $0.07 per kWh. These utility costs, aside from those provided by the current clinical 
facility, will be ignored when costing each individual treatment. 
 The media and other buffers used to suspend the T-cells when they are growing must be 
removed before the final product is sent back to the patient. These fluids must be considered 
biohazard material and disposed of appropriately. At laboratory scales the used media is 
combined with bleach and dumped down the drain. The large scale production facility will likely 
not be able to use this simple method to dispose of the media and will instead incur costs of 10% 
of the cost of the material.  
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9.1: Major process equipment costs 
The initial plant will contain 20 individual cell processing rooms, capable of producing the therapy for 
approximately 33 patients each year. The quantity of each equipment required can be assumed to scale 
directly with the number of cell processing rooms. This assumption was also made in determining the 
additional cost of expanding the facility in future years. 
Table 9.1: List of major operating equipment 
Component Name Quantity Vendor Cost 
P-07 MaxSep Magnetic 
Separators  
8 Baxter $1165 
P-02 Elutra 4 Terumo $55000 
P-03/08 Cell Saver 5 Autologous 
Blood Recovery 
Systems 
12 Haemonetics $18500 
P-04 CliniMACS Magnetic 
Separator 
8 Miltenyi $55000 
P-06 WAVE 2/10 Bioreactor 16 GE Healthcare Life 
Sciences 
$47500 
 
Bare module costs will not be accounted for because all of the equipment is delivered 
assembled. Aside from certain calibrations, all equipment listed in table 9.1 can be used as is. 
Most of the additional equipment also do not require assembly and will exclude bare module 
costs from the total capital investment. Exceptions include the laminar flow hood, however these 
do not represent a significant contribution to the total cost of equipment and will be assumed as 
negligible. 
All costs for equipment, including the additional equipment in section 9.2 were obtained 
directly from the equipment supplier websites. If a precise quote was unavailable, pricing data 
was found for similar equipment from other suppliers or from bulk, industrial suppliers, such as 
www.alibaba.com. 
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9.2: Additional equipment costs 
Table 9.2: List of additional operating equipment 
Additional Equipment 
Name Quantity Vendor Cost 
4’ Laminar Flow Hood 10 Air Science $1000 
6’ Laminar Flow Hood 24 Air Science $1600 
9050 Blood Culturing System 6 BACTEC $21105 
LSRFortessa  Flow Cytometer 2 BD  $1165 
Calibur Flow Cytometer 2 FACS $29500 
M/M3 Cell Counter/ Sizers 8 Beckman Coulter $5000 
Digital Balance 36 Taylor Precision $200 
HEPA Filtered CO2 Incubator 34 Sanyo $1500 
LN2 Freezer 22 LABRepCo $25000 
LN2 Manifold Changeover 2 Airgas $3353 
Luminometer 2 Promega $80 
Microcentrifuge 22 Corning $300 
Biofuge primoR Centrifuge 2 Sorvall $3381 
Legend RT Centrifuge 24 Sorvall $8774 
RC3B-plus Centrifuge 4 Sorvall $5000 
Microscope 26 AmScope $350 
-30oC Freezer 6 True $8000 
-40 oC Freezer 2 True $9500 
-80 oC Freezer 8 True $9500 
Controlled Rate Freezer 10 True $20336 
Double Door Refrigerator 10 Custom Biogenic Systems $400 
Under-Counter Refrigerator 28 Avanti $700 
Upright Refrigerator 4 Kenmore $300 
Refrigerator/Freezer Combo 2 Kenmore $200 
Chromatography Refrigerator 4 Thermo Scientific $6625 
Plate Washer 2 Tecan $1000 
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Sebra Heat Sealer 32 Haemonetics $5400 
Spectrophotometer 2 Thermo Scientific $10000 
Table-top CO2 Incubator 4 Panasonic $5000 
Sterile Connecting Device 30 Terumo $1500 
Total Air Particle Counters 4 Lighthouse $1000 
Viable Air Particle Sampler 2 Beckman Coulter $1700 
Water bath 34 Thermo Scientific $150 
 
9.3: Building construction costs 
Using data provided by the head architect of the existing clinical trial facility, a facility 
with 20 cell processing rooms, including quality control, freezer rooms, office space, and 
additional cGMP space requires 13,000 ft2. High specialized space like the cGMP environment 
and the rest of the processing plant require extremely high construction costs and will likely be 
constructed within an existing hospital network building to take advantage of HEPA filtration 
capabilities and waste and consumable disposal. The construction costs for such a space will be 
$800/ft2. The initial facility space will cost $10,400,000 to construct.  
 
9.4 Individual treatment cost summary  
It is easiest to calculate the costs incurred to the lab by looking at the costs of an 
individual treatment. While the actual cost of each treatment varies slightly due to the fluctuation 
in the volume and concentration of the blood received from the patient, a typical cost will be 
used to represent the average batch for profit analysis purposes. Table 9.3 contains a list of the 
specific costs that must be accounted for the production of the therapy for one patient. 
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Table 9.3: List of costs incurred for single treatment 
Average Process Costs 
Component Cost 
Apheresis $1500 
Media  $10000 
Disposal Costs $1000 
Ex-vivo Expansion $1400 
Suppressor Protein Removal $600 
Quality Control $6000 
Consumables $800 
Usage of facility (Staff/electricity) $2700 
Overhead Costs/Other $2000 
Total $26000 
 
9.5 Overall process costs 
The total cost of equipment for a new facility with 20 cell processing rooms will be 
$3,513,814. This, along with the cost of building construction, represents a capital investment 
that must be depreciated. Most capital investments in the pharmaceutical industry use the 
Modified Accelerated Cost Recovery System for calculating depreciation. On the 5-year model, 
the subsequent years of depreciation are 20%, 24.49%, 19.2%, 11.52%, 11.52% and 5.76%.  
The individual treatment cost of $26000 includes components such as electricity and staff 
salaries that would typically be considered fixed costs. The current clinical facility calculates 
costs in the manner displayed in table 9.3 and we will thus also consider these utilities and 
services as variable costs. General fixed costs will be assumed to be 15% of the variable costs for 
the first year or $2,600,000. 
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Chapter 10: Economic analysis 
10.0 Economic analysis 
The adoptive T-cell therapy presents many advantages to the existing forms of treatment 
for ALL including greater efficacy, shorter timeframe for results, fewer side effects and the 
patient specificity. When used in conjunction with stem cell transplantation, this therapy has the 
potential to cure virtually all cases of ALL. However, it will be unrealistic to consider the large 
scale production of this therapy if it is not economically viable. An analysis of the profitability 
will be used to determine how the drug should be priced as well as consider the scale-up of the 
current facility to meet the demands of the patient population. 
10.1 Market analysis 
While there are a few research teams currently conducting clinical trials of adoptive T-
cell therapy, no such therapy has yet been brought to market. The only comparable 
immunotherapy that has been FDA approved is Blincyto, a drug that channels T-cells towards 
CD19 expressing tumor cells. A standard course of treatment for Blincyto runs at $178,000. This 
cost is exorbitantly high and would likely prohibit many patients, even those who are insured, 
from utilizing this treatment. Typical costs incurred by ALL patients undergoing chemotherapy 
today range from $54,587 to upwards of $126,613 (Tong, et al) for a complete course of 
treatment. This price accounts for drugs, additional medication, daycare treatment (for young 
patients), inpatient care, blood products, laboratory activities, and other hospital activities. The 
cost of the adoptive T-cell therapy would likely be $100,000 for the complete treatment, a 
reasonable price when considering the increased efficacy as well as the cost of competing 
alternatives.  
However it would be unrealistic to expect the new facility to be capable of treating the 
entire ALL patient population in the geographic area. The primary determinant of the production 
capability of the facility is the number of cell processing rooms. Each cell processing room can 
handle a single patient at a time and typically takes nine days per patient. The facility operates 
300 days a year with most capacity during the standard hours of 9am to 5pm, while the WAVE 
bioreactors are monitored and running throughout the night. The initial plant will contain twenty 
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cell processing rooms to reduce the upfront capital investment as well as reduce the risk 
associated with introducing a new product to the market. If unforeseen issues with production of 
the treatment arise, there will be less capital at stake. It is expected that every three years, for the 
life of the twelve year process, an additional ten cell processing rooms will be added to the 
facility, resulting in fifty rooms in the final three years.  
An initial facility with a larger capacity was not built, because it would be difficult to 
justify the almost doubling of initial capital costs for marginal increase in the net present value. 
Particularly in an industry as volatile as the healthcare payer industry, beginning with a smaller 
facility would be advisable.   
The first year of production with the new facility will have the capacity to produce the 
treatment for 667 patients, although clinical trial data indicates it is likely that approximately 
10% of the batches will fail due to unforeseen problems with growing the cells or the patient 
dying before the treatment is completed, but will still incur the costs of production. This typically 
occurs when the separation equipment is unable to obtain a large enough concentration of the 
desired T-cells. We expect that this percentage will decrease to 5% by the seventh year as the 
team gains experience with the process and minimizes all potential sources for error. In the 
optimization of the Elutra Cell Separating System, we expect that the proper utilization of our 
designed operating conditions will be able to significantly reduce the chance of a faulty 
separation to a 1% failure rate. In the economic analysis data presented in the appendix, we 
consider both operating scenarios (1% failure versus a transition from 10% to 5%).  
Using these production specifications, the facility will attempt to treat 667 patients in the 
first year and a total of 14,000 patients over the course of the twelve years.  
10.2 Profitability analysis 
A cost of capital of 15% and a corporate tax rate of 35% were used to calculate important 
profitability information. The interest rate was not higher, because the risk associated with this 
product should not be particularly high, given the extremely promising results from clinical 
trials.  
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For the operation of the facility with the Elutra settings currently used, the Net Present 
Value (NPV) for the 12 year project is $214,821,709. The Internal Rate of Return (IRR) on such 
a facility would be 300.01% and the Return on Investment (ROI) would be 138.47%. All three of 
these numbers indicate that the project would be good investments and could potentially lead to a 
successful company. Using a 15% Cost of Capital, the product pricing that will lead to an NPV 
of 0 is $33,884. This product pricing for a “15% company” would be significantly lower than 
competitor products. At a fraction of the cost of other alternatives, the adoptive T-cell therapy 
has the potential to almost guarantee a complete remission of ALL.  
While some insurance companies may attempt to avoid completing claims filed for novel 
therapies, such as the adoptive T-cell therapy, this is relatively easily dealt with. Most health 
insurance companies, when provided with reports documenting the efficacy of the treatment for 
the particular form condition, along with statements from medical professionals, will agree to 
cover the treatment (American Cancer Society)1. 
The utilization of our design protocol for the Elutra will only increase the appeal of this 
process. By improving the separation of the sample, the chance of failure would decrease. When 
each failed treatment results in a direct loss of revenue, this design result has the potential to 
improve all of the financial identifiers. The designed facility would have an NPV of 
$238,742,275, or $23,920,566 more than the current facility conditions. The IRR would also be 
343$ and the ROI 158.04%.  
10.3 Sensitivity analysis 
A sensitivity analysis was conducted on three factors: the price of the product, the cost of 
production for a treatment, and the failure rate for the process. The results of this analysis are 
presented in the appendices, but will be summarized here. A comparison of the effects that 
variations in the price of the product and the failure rate can have on the NPV shows a large 
range of NPV values for the observed scenarios. While the failure rate varies from 10% to 0%, 
the NPV fluctuates from $410.5 million all the way up to an impressive $418 million. However, 
trends in the data show that even increases of 2-3% on the failure rate could drop the NPV of the 
project by several million dollars. The price of the product has a potentially even larger effect on 
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the NPV. Regardless, it does not seem likely that the NPV could drop below $0, so it is safe to 
say that this will be an advisable investment.  
In the second sensitivity analysis, the variable costs per treatment were varied at a given 
failure rate of 1%, as expected from the newly designed Elutra. Both the product price and 
production costs were varied within ±50% of the original value, and all resulting NPV values 
remained above zero. However at low prices and high costs the NPV drops as low as $110.5 
million, with the product price having the stronger influence on the NPV.  
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10.4: Chapter 4 References 
1. Paying for chemo treatment. (2014, August 24). Retrieved April 14, 2015, from 
http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/chemotherapy/
under-chemotherapy-paying-for-chemo 
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Chapter 11: Conclusions and recommendations 
The proposal for an adoptive T-cell therapy facility details the process currently being 
performed in clinical trials at the Hospital of the University of Pennsylvania under a team led by 
Dr. Bruce Levine. The therapy specifically treats acute lymphoblastic leukemia by reengineering 
the patient’s own T-cells to specifically target the tumor cells. Success of the treatment relies on 
a successful separation and re-concentration of the patient’s white blood cells before the 
modifications are made using certain gene vectors. A WAVE bioreactor is utilized to expand all 
transformed cells to concentrations large enough for injection back into the host patient. The 
facility can exist in collaboration with external clinics where apheresis is conducted and blood 
products are transferred to the main processing center. Proper production of the treatment must 
be conducted within cGMP conditions, which require specialized facility construction and 
regulation.  
To improve the success rate of the overall procedure, we first identified a step in the 
process that was largely responsible for process failure. This step was the separation of 
erythrocytes from leukocytes.  By modeling counterflow centrifugal elutriation, we were able to 
determine how various operating parameters, such as rotation frequency, buffer flowrate, and 
buffer density, affected the residence times of leukocytes and erythrocytes. Through Matlab 
simulations, we found an ideal operating condition that would essentially provide a perfect 
separation between erythrocytes and leukocytes with a difference in average residence times of 
infinity. This led us to propose an operating procedure for CCE, which was to first run the 
separation at 20 mL/min for one minute, then increase the flowrate and run the separation at 60 
mL/min for another minute. We estimate that our proposed protocol will reduce the failure rate 
from 10% to 1%, increasing the overall profitability of the procedure.   
This therapy will be the first of its kind to obtain FDA approval. The only other 
immunotherapy currently on the market is a drug that costs $178,000 per treatment and has 
shown almost half the efficacy of the T-cell treatment. At a cost of $100,000 this therapy would 
be priced competitively with other existing options for patients with severe ALL. The proposed 
facility will attempt to treat a significant portion of the ALL population located in the Northeast 
region of the United States. Assuming a typical patent life, the product will have a 12 year life-
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span. Beginning with a smaller facility to reduce initial capital costs and minimize financial risk, 
the facility will treat approximately 667 patients annually, but will scale-up every three years to 
treat up to 1667 patients per year for its last three years of operation. Utilizing the results from 
the Elutra design, the failure rate of the process should be minimized to 1% per year. Using all 
economic data available about the current process, the NPV, IRR and ROI for the designed 
facility would be $238,742,275, 343% and 158.04%, respectively. This would represent a more 
than $23 million increase in the NPV from a facility operating under the existing conditions. All 
three of these values indicate that the proposed facility would be an excellent investment 
opportunity.  
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Appendix A: Stoichiometry of animal cell growth 
 
C6H12O6 + pC5H10O3N2 + qO2 → rCH1.82O0.84N0.25 + sC3H3O3 +tNH3 +uCO2 + vH2O 
 
Molecular Formula Name Coefficient 
C6H12O6 Glucose  1 
C5H10O3N2 Glutamine p 0.52 
O2 Oxygen q 1.64 
CH1.82O0.84N0.25 Biomass (t-cell) r 1.52 
C3H3O3 Lactic Acid s 1.80 
NH3 Ammonia t 0.66 
CO2 Carbon Dioxide u 1.67 
H2O Water v 0.82 
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Appendix B: Sample calculations 
Calculation of sphericity of erythrocyte 
Volume of erythrocyte = ¼ π * t * D2 = ¼ π * 2 * 72 = 76.97 μm3 
Diameter of sphere = (6 * volume of erythrocyte * (1/π))1/3 = (6 * 76.97 * (1/π))1/3 = 5.28 μm 
Surface area of sphere = πD2 = π(5.28)2 = 87.5 μm2 
Surface area of erythrocyte = ½ π D2 + πDt = ½ * π * (7)2 + π * (7) * 2 = 120.95 μm2 
Sphericity = 87.5/120.95 = 0.723 
Calculation of Sauter mean diameter 
Vp = ¼ π D
2 * t = ¼ π 72 * 2 = 77.0 μm3 
Ap = ½ π D
2 + πDt = ½ * π * (7)2 + π * (7) * 2 = 120.95 μm2 
dsd = 6 * (Vp/Ap) = 3.82 μm 
Calculation of effective diameter 
deff = dsd * sphericity = 0.723 * 3.82 = 2.76 μm 
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Appendix C: Matlab script 
%TubeODE45 
%%Function 
function output=tube(t,r); 
mp=1.21e-14; 
mu=6.53e-4; 
Dp=2.76e-6; 
pp=1100; 
pf=1000; 
omega=251; 
D=0.00714; 
R=0.152; 
Ro=0.102; 
Ri=0.202; 
Q=-1.67e-6; 
Uf=Q/(pi()*(D/2)^2); 
A=(3*pi()*mu*Dp)/mp; 
B=((pi()/6)*Dp^3*(pp-pf)*omega^2)/mp; 
C=(3*pi()*mu*Dp*Uf)/mp; 
output=zeros(2,1); 
output(1)=r(2); 
output(2)=-A*r(2)+B*r(1)+C; 
end 
 
%%RunningCode 
clear all; 
time_period=[0 10]; 
Ri=0.202; 
initial=[Ri,0]; 
[t,r]=ode45(@tube,time_period,initial) 
plot(t,r(:,1)), title('displacement') 
xlabel('time(s)') 
ylabel('r(m)') 
figure 
plot(t,r(:,2)), title('velocity') 
xlabel('time(s)') 
ylabel('velocity(m/s)') 
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Appendix E: Vendor specification sheets and MSDS 
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